¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"migratory inhibitory factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ
  • antisterility factor
    Ç׺ÒÀÓÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ³ªÆ®·ýÀÌ´¢ÀÎÀÚ, ½É¹æ¼ÒµãÀÌ´¢ÀÎÀÚ
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • alveolar dilution factor
    ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
  • amplification factor
    ÁõÆøÀÎÀÚ
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • colony-stimulating factor
    Áý¶ôÀÚ±ØÀÎÀÚ
  • common factor
    °øÅëÀÎÀÚ
  • competence factor
    1. ¸é¿ª°¡´ÉÀÎÀÚ 2. ¹ÝÀÀ°¡´ÉÀÎÀÚ
  • competence inducing factor
    ¸é¿ª°¡´ÉÀ¯¹ßÀÎÀÚ
  • complementary factor
    º¸ÃæÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ
  • antiphagocytic factor
    Çׯ÷½ÄÀÛ¿ëÀÎÀÚ
  • antirachitic factor
    Ç×±¸·íº´ÀÎÀÚ
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ
  • antisterility factor
    Ç׺ÒÀÓÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ³ªÆ®·ýÀÌ´¢ÀÎÀÚ
  • colonizing factor antigen
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • carcinogenic factor
    ¹ß¾ÏÀÎÀÚ
  • chemotactic factor
    È­ÇÐÁÖ¼ºÀÎÀÚ, È­Çнò¸²ÀÎÀÚ
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • colony-stimulating factor
    Áý¶ôÀÚ±ØÀÎÀÚ
  • common factor
    °øÅëÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Christmas factor
    Å©¸®½º¸¶½º ÀÎÀÚ(ì×í­)
  • Christmas factor.
    Å©¸®½º¸¶½ºÀÎÀÚ
  • D factor
    DÀÎÀÚ
  • Decay accelerating factor
    ºØ±«°¡¼Ó¿ä¼Ò(¿äÀÎ)
  • EDCF (endothlium-derived contracting factor)
    ³»ÇǼ¼Æ÷¼º(Ò®ù«á¬øààõ) ¼öÃàÀÎÀÚ(â¥õêì×í­)
  • EDRF (endothlium-derived relaxing factor)
    ³»ÇǼ¼Æ÷¼º(Ò®ù«á¬øààõ) ÀÌ¿ÏÀÎÀÚ(ì¬èÐì×í­)
  • EDRF=£¾endothelium derived relaxing factor
    ³»ÇǼ¼Æ÷¼ºÀÌ¿ÏÀÎÀÚ.
  • F factor
    FÀÎÀÚ
  • Factor IX
    IX ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Factor V
    V ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Factor VII
    VII ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Factor VIII
    VIII ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Factor X activated
    Ȱ¼ºÈ­(üÀàõûù)µÈ X ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Factor XI
    XI ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Factor XII
    XII ÀÀ°íÀÎÀÚ(ëêͳì×í­)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inhibitory junctional potential
    ¾ïÁ¦¼º Á¢ÇÕºÎÀü¾Ð(ïÈùêݬï³äâ).
  • inhibitory nerve
    ¾ïÁ¦½Å°æ.
  • inhibitory nerve
    ¾ïÁ¦½Å°æ(åäð¤ãêÌè).
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
  • inhibitory postsynaptic potential = IPSP
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º.
  • inhibitory synapse
    ¾ïÁ¦¼º(åäð¤àõ) ½Ã³³½º.
  • inhibitory transmitter
    ¾ïÁ¦¼º Àü´Þ¹°Áú.
  • inhibitory zone
    ¾ïÁ¦¹üÀ§(åäð¤ÛôêÌ).
  • minimal inhibitory concentration
    ÃÖÀú¹ßÀ°ÀúÁö³óµµ(õÌî¸Û¡ëÀðæò­ÒØöô).
  • minimum inhibitory concentration
    ÃÖ¼Ò¹ßÀ°ÀúÁö³óµµ(õÌá³Û¡ëÀîÁò­ÒØöô).
  • minimum inhibitory concentration
    ÃÖ¼Ò¾ïÁ¦³óµµ
  • minimum inhibitory concentration
    ÃÖ¼Ò¹ßÀ°ÀúÁö³óµµ(̧ËÛËÑËôËøÌ¤ËÀ̬).
  • minimum inhibitory dose
    ÃÖ¼Ò¾ïÁ¦·®(¡­åäð¤åÖ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antixerophthalmic factor
    Ç׾ȱ¸ °ÇÁ¶Áõ ÀÎÀÚ(ù÷äÑϹËëðÏñøì×í­)
  • Arrenius factor
    ¾Æ·¹´Ï¿ì½º ÀÎÀÚ(ì×í­)
  • asymmetry factor
    ºñ±¸»ó ÀÎÀÚ (ުϹßÒì×í­)
  • atrial natriuretic factor
    ½É¹æ(ãýÛ®) ³ªÆ®·ý¹è¼³ÀÎÀÚ(ÛÉàÜì×í­)
  • bacteriocin factor
    "¹ÚÅ׸®¿À½Å ÀÎÀÚ(ì×í­), »ì±ÕÀÎÀÚ(߯жì×í­)"
  • binding factor
    °áÇÕÀÎÀÚ(Ì¿ùêì×í­)
  • calcium-activated factor
    Ä®½·ºÎȰ ÀÎÀÚ(Ý·üÀì×í­)
  • cell factor
    ¼¼Æ÷ÀÎÀÚ(á¬øàì×í­)
  • chloroplast coupling factor
    ¿±·Ïü(ç¨Öàô÷) ¦ÁöÀ½ÀÎÀÚ(ì×í­)
  • Christmas factor
    Å©¸®½º¸¶½º ÀÎÀÚ(ì×í­)
  • citrovorum factor
    "½ÃÆ®·Îº¸·ë ÀÎÀÚ,"
  • clearance factor
    ûÁ¤ÀÎÀÚ(ôèïäì×í­)
  • clot-promoting factor
    ÀÀ±«ÃËÁøÀÎÀÚ(ëêÎÕõµòäì×í­)
  • Col factor
    Col ÀÎÀÚ(ì×í­)
  • colicin factor
    Äݸ®½Å ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PIF   1) Proliferation Inhibitory Factor
  2) Prolactin release Inhibiting Factor...
DF decapacitation factor; decontamination factor; deferoxamine; deficiency factor; defined flora [anima...
GRF gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow...
HSF heat shock factor; hepatocyte stimulatory factor; histamine sensitizing factor; human serum esterase...
LPF leukocytosis-promoting factor; leukopenia factor; lipopolysaccharide factor; localized plaque format...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
OCIF Osteoclastogenesis inhibitory factor
LIFR leukemia inhibitory factor receptor
DNIC diffuse noxious inhibitory control
EIC Elastase inhibitory capacity
XIP Exchange-inhibitory peptide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • anisotropy factor
    ºñµî¹æ¼º °è¼ö
  • antiangiogenesis factor
    Ç×Ç÷°ü»ý¼º ÀÎÀÚ
    Harvard ´ëÇп¡¼­ ¿¬±¸µÈ °ÍÀε¥ ¿¬°ñ¿¡´Â ¸ð¼¼Ç÷°üÀÌ Ä§ÅõµÇÁö ¾Ê´Â Çö»óÀ» °üÂûÇÏ°í ¾Ï Á¶Á÷¿¡ ¿¬°ñÁ¶Á÷¿¡¼­ À¯·¡µÈ antiangiogenesis factor¶ó´Â °ÍÀ» »ç¿ëÇÏ¿© ¾Ï Á¶Á÷ÀÇ ¼èÅ𸦠ÃÊ·¡ÇÏ¿´´Ù.
  • antihemophilic factor
    Ç×Ç÷¿ìº´ ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰 ÀÎÀÚ
  • antistiffness factor
    Ç×°­Á÷ ÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ¼º ³ªÆ®·ý ÀÌ´¢ ÀÎÀÚ
  • attenuation factor
    °¨¾à ¿ä¼Ò, °¨¼è ¿äÀÎ
  • B cell growth factor
    B ¼¼Æ÷ ¼ºÀå ÀÎÀÚ, B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ
    B ¼¼Æ÷°¡ ÇüÁú ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â °úÁ¤Àº Å©°Ô 2´Ü°è·Î ³ª´©¾îÁø´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ¿ì¼± Áõ½ÄÇϰí, ±× ÈÄ¿¡ Ç×ü¸¦ »ý»êÇÏ¿© ºÐºñÇÏ´Â ÇüÁú ¼¼Æ÷·Î ºÐÈ­¸¦ ¿Ï¼öÇÑ´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ±× ÀÚÁ¦¸¸À¸·Î´Â Áõ½ÄÇÏÁö ¸øÇϰí T¼¼Æ÷ À¯·¡ÀÇ B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ³ª Ž½Ä ¼¼Æ÷ À¯·¡ ÀÎÀÚ IL-1ÀÇ ÀÚ±ØÀÌ Ãß°¡µÇ¾î Áõ½ÄÀ» ½ÃÀÛÇÑ´Ù. B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ´Â Á¤»óÀÇ T¼¼Æ÷¸¦
  • B cell stimulating factor 1
    B ¼¼Æ÷ ÃËÁø ÀÎÀÚ 1
    µ¿ÀǾî´Â Interleukin 4·Î ¾Ë·ÁÁø ´ç´Ü¹éÀ¸·Î¼­ T ¼¼Æ÷, ºñ¸¸¼¼Æ÷ µî¿¡¼­ »ý»êµÈ´Ù. À̰ÍÀº B ¼¼Æ÷¿¡ ´ëÇØ comitogenÀ¸·Î ÀÛ¿ëÇϴµ¥ ±× ¿µÇâÀº B ¼¼Æ÷ÀÇ ¼º¼÷µµ¿¡ µû¶ó ´Ù¸£´Ù.
  • back scatter factor
    ÈÄ¹æ »ê¶õ °è¼ö
  • beam direction factor
    ¼±¼Ó ¹æÇâ ÀÎÀÚ
    ÀüÀÚÆÄ ¹æ»ç¼± ¶Ç´Â ÀÔÀÚ°¡ °°Àº ¹æÇâÀ¸·Î ¹æÃâÇÏ ´Â ¼Ó ¶Ç´Â ¼±ÀÇ ¹æÇâÀÇ ÀÎÀÚ.
  • behavioral factor
    Çൿ ¿äÀÎ
  • biological factor
    »ý¹°ÇÐÀû ¿äÀÎ
  • biotic factor
    »ý¹° ÀÎÀÚ
  • blood factor
    Ç÷¾× ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
antiberiberi factor Synonym: thiamin.
(05 Mar 2000)
anti-black-tongue factor A precursor of NAD, that is a product of the oxidation of nicotine.
(18 Nov 1997)
anticomplementary factor A factor that interferes with the action or function of complement.
(05 Mar 2000)
antidermatitis factor <chemical> Chemical name: beta-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (R)-
(12 Dec 1998)
antihemophilic factor A A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs.
(12 Dec 1998)
antihemophilic factor B <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
antihemorrhagic factor <biochemistry> A fat soluble vitamin that plays an important role in blood clotting.
(27 Sep 1997)
antineuritic factor A member of the water-soluble B vitamin group, necessary for energy production and carbohydrate metabolism. Deficiency is known as beriberi.
(27 Sep 1997)
antinuclear factor A factor, usually antibodies, present in serum with strong affinity for nuclei and detected by fluorescent antibody technique; present in lupus erythematosus, rheumatic arthritis, and certain other autoimmune conditions; may also be present at lower levels in normal individuals.
(05 Mar 2000)
antipellagra factor A precursor of NAD, that is a product of the oxidation of nicotine.
(18 Nov 1997)
antipernicious anaemia factor <biochemistry> Member of the water soluble B vitamin group, important in the proper function of the nervous system and important in proper carbohydrate, protein and fat metabolism.
(27 Sep 1997)
antisterility factor <biochemistry> Functions as an antioxidant, binds oxygen free radicals that can cause tissue damage, may also play a protective role in the coronary arteries from the damaging effects of cholesterol.
(27 Sep 1997)
antitermination factor <molecular biology> A gene regulatory protein that blocks signals for the transcription process to stop as a form of regulatory control over whatever the gene being transcribed is coding for.
(13 Jan 1998)
atrial natriuretic factor <chemical> A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight peptides derived from a common precursor and secreted by the heart atria. All these peptides share a sequence of about 20 amino acids.
Chemical name: Atriopeptin
(12 Dec 1998)
attenuation factor <radiobiology> A measure of the opacity of a layer of material for radiation transversing it, the ratio of the incident intensity to the transmitted intensity. It is equal to Io/I, where Io and I are the intensities of the incident and emergent radiation, respectively. In the usual sense of exponential absorption (I = Ioe- m x), the attenuation factor is e- m x, where x is the thickness of the material and m is the absorption coefficient.
(16 Dec 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á